This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Renal Diseases  • Dialysis  • Randomized Controlled Trial  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2007;298(17):1995-1996.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A costly and widely used medication for patients on hemodialysis is no better at reducing mortality than lower-cost alternatives, according to the findings of a new study.

In the largest prospective randomized study to date comparing patients on hemodialysis who were given sevelamer hydrochloride (Renagel, Genzyme Corporation, Cambridge, Mass) or a calcium-based binder to treat hyperphosphatemia, the Dialysis Clinical Outcomes Revisited (DCOR) trial, researchers found that all-cause mortality was the same in the group taking sevelamer (267 deaths) and the group taking a calcium-based binder (275 deaths) (Suki WN et al. Kidney Int. doi:10.1038/sj.ki.5002466 [published online ahead of print August 29, 2007]).

Maintaining appropriate levels of phosphate is important for patients on hemodialysis, but the best way to do so remains open to debate. (Photo credit: AJPhoto/www.sciencesource.com)

However, in a prespecified secondary analysis of the trial (which was sponsored by Genzyme), the researchers did find . . . [Full Text of this Article]

GETTING RID OF PHOSPHATE



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Phosphorus Binders and Survival on Hemodialysis
Isakova et al.
J. Am. Soc. Nephrol. 2009;20:388-396.
ABSTRACT | FULL TEXT